Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Kedoya Adyaraya Tbk (RSGK.JK)
Jakarta Barat, ID
PT Kedoya Adyaraya Tbk operates as an Indonesian healthcare enterprise, managing and owning hospitals throughout the country. The company delivers a broad spectrum of medical services across numerous specialties, encompassing comprehensive surgical procedures such as general, orthopedic, urological, cardiothoracic, plastic, and neurological operations. It also provides internal medicine subspecialties like nephrology, endocrinology, and general internal medicine, alongside care in obstetrics and gynecology, cardiology, neurology, pulmonology, ophthalmology, hyperbaric medicine, and pediatrics. Additional services include acupuncture, medical rehabilitation, and speech therapy. Oral health is addressed through oral and maxillofacial services, prosthodontics, and general dentistry. Furthermore, mental health support is provided by psychiatrists and psychologists, nutritional guidance by dietitians, and specialized treatment for skin and venereal conditions. Beyond these specialized areas, the company also offers general medical care. As of December 31, 2021, PT Kedoya Adyaraya Tbk operated two hospitals, offering a combined capacity of 200 patient beds. Established in 1990, the company's main office is located in Jakarta Barat, Indonesia, and it functions as a subsidiary of PT Sarana Meditama Metropolitan Tbk.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.55% | +7.69% | -28.73% | +0.00% | +0.00% | +0.00% | +0.00% | -8.41% | -54.42% | -54.42% | -54.42% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Care Facilities: +10.2%+18.1% ★ Q2'25: +4.7% (vs Q2'24)
-
EPS growth Medical - Care Facilities: +19.2%+57.6% ★ Q2'25: +11.0% (vs Q2'24)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+8.5% ★ Q2'25: -9.0% (vs Q2'24)
-
EBIT margin Medical - Care Facilities: +11.3%+12.9% ★ Q2'25: +12.3% (vs Q2'24)
-
ROIC Medical - Care Facilities: +6.8%+5.4% Q2'25: +5.4% (vs Q2'24)
-
Share dilution Medical - Care Facilities: +0.0%+0.0% Q2'25: +0.0% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×0.00× ★ Q2'25: 0.47× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Agnes Pricilia Suryanto | Head of Internal Audit Unit | — | female |
| Agus Rosyadi | Corporate Secretary | — | — |
| Juniwati Gunawan | President Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RSGK.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
